ADMA Biologics Inc (ADMA)
21.30
-0.07
(-0.33%)
USD |
NASDAQ |
Nov 21, 16:00
21.29
-0.01
(-0.05%)
After-Hours: 20:00
ADMA Biologics Enterprise Value: 5.050B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 5.050B |
| November 20, 2024 | 5.066B |
| November 19, 2024 | 4.891B |
| November 18, 2024 | 4.634B |
| November 15, 2024 | 4.515B |
| November 14, 2024 | 4.790B |
| November 13, 2024 | 5.090B |
| November 12, 2024 | 5.163B |
| November 11, 2024 | 5.329B |
| November 08, 2024 | 5.362B |
| November 07, 2024 | 4.676B |
| November 06, 2024 | 4.664B |
| November 05, 2024 | 4.466B |
| November 04, 2024 | 4.532B |
| November 01, 2024 | 4.593B |
| October 31, 2024 | 3.870B |
| October 30, 2024 | 4.024B |
| October 29, 2024 | 3.965B |
| October 28, 2024 | 3.898B |
| October 25, 2024 | 3.752B |
| October 24, 2024 | 3.787B |
| October 23, 2024 | 3.723B |
| October 22, 2024 | 3.719B |
| October 21, 2024 | 3.707B |
| October 18, 2024 | 3.745B |
| Date | Value |
|---|---|
| October 17, 2024 | 3.825B |
| October 16, 2024 | 3.901B |
| October 15, 2024 | 3.934B |
| October 14, 2024 | 3.884B |
| October 11, 2024 | 4.067B |
| October 10, 2024 | 4.035B |
| October 09, 2024 | 4.819B |
| October 08, 2024 | 4.912B |
| October 07, 2024 | 4.785B |
| October 04, 2024 | 4.811B |
| October 03, 2024 | 4.641B |
| October 02, 2024 | 4.624B |
| October 01, 2024 | 4.688B |
| September 30, 2024 | 4.740B |
| September 27, 2024 | 4.561B |
| September 26, 2024 | 4.574B |
| September 25, 2024 | 4.586B |
| September 24, 2024 | 4.539B |
| September 23, 2024 | 4.711B |
| September 20, 2024 | 4.700B |
| September 19, 2024 | 4.644B |
| September 18, 2024 | 4.546B |
| September 17, 2024 | 4.404B |
| September 16, 2024 | 4.285B |
| September 13, 2024 | 4.259B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
185.96M
Minimum
Mar 18 2020
5.362B
Maximum
Nov 08 2024
882.08M
Average
467.50M
Median
Apr 04 2022
Enterprise Value Benchmarks
| Corcept Therapeutics Inc | 5.479B |
| Madrigal Pharmaceuticals Inc | 6.299B |
| Assembly Biosciences Inc | 0.5176M |
| TG Therapeutics Inc | 5.281B |
| Krystal Biotech Inc | 4.654B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 35.91M |
| Revenue (Quarterly) | 119.84M |
| Total Expenses (Quarterly) | 80.20M |
| EPS Diluted (Quarterly) | 0.15 |
| Gross Profit Margin (Quarterly) | 49.78% |
| Profit Margin (Quarterly) | 29.96% |
| Earnings Yield | 1.31% |
| Operating Earnings Yield | 2.27% |
| Normalized Earnings Yield | 1.315 |